Tag archive for ‘Clal Biotech’
Gil Tanenbaum On Monday, October 27th, 2014

Clal Biotech Sells Pidilizumab Cancer Treatment Rights to Medivation

Israel’s Clal Biotechnology Industries has sold the exclusive worldwide commercialization rights for its cancer treatment pidilizumab to the American company Medivation. The rights are held by Clal subsidiary More...

Globes On Tuesday, October 7th, 2014

Clal Biotech, Hyperion seek settlement over Andromeda

– Clal Biotechnology and Hyperion have agreed on an independent assessment of Andromeda’s Type 1 diabetes treatment. –   Clal Biotechnology (TASE: CBI), managed by Reuven Krupik, and More...

Globes On Tuesday, September 23rd, 2014

Clal Biotech Suing Hyperion for $200 Million over ‘Rash and Ill Considered’ Andromeda Decisions

Clal Biotechnology Industries Ltd. (TASE: CBI announced yesterday that it had filed a $200 million suit against drug company Hyperion Therapeutics Inc. (Nasdaq: HPTX) in the US in the State of Delaware Court, More...

ANDROMADA
Jewish Business News On Monday, September 22nd, 2014

Clal Biotech: No Evidence of Misconduct by Us

Clal Biotechnology Industries Ltd. (TASE: CBI) notified the Tel Aviv Stock Exchange this morning that it had contacted Hyperion Therapeutics Inc. (Nasdaq: HPTX) as part of its efforts to gather as much information More...

health
Koby Yeshayahou On Wednesday, February 26th, 2014

Clal Biotech Selling Diabetes Treatment Co Andromeda

– Clal Biotechnology Industries Ltd. (TASE: CBI) has signed a non-binding letter of intent to sell diabetes treatment developer Andromeda Biotech Ltd. to a US pharmaceutical company for an immediate More...

Gali Weinreb On Monday, February 3rd, 2014

More Israeli Life Sciences Companies Going To Nasdaq

– The burn and wound treatment company MediWound plans to raise $100m on Nasdaq at a $400 million valuation.  – In the coming weeks, several Israeli life sciences companies will examine whether More...

Wordpress site Developed by Fixing WordPress Problems